Markets:

Overview

News

Currencies

International

Treasuries

Aurinia Pharmaceuticals Inc - Common Shares (NQ:AUPH)

14.77 +0.40 (+2.75%)

Streaming Delayed Price Updated: 12:30 PM EDT, Mar 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Aurinia Pharmaceuticals Inc - Common Shares

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results

January 05, 2024

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Submits IND Application to US Food & Drug Administration for AUR 200

December 20, 2023

From Aurinia Pharmaceuticals Inc.

Via Business Wire

What's Going On With Aurinia Pharmaceuticals Stock? ↗

November 20, 2023

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares are trading higher, adding to gains of more than 17% over the last week.

Via Benzinga

Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan

November 13, 2023

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Why Aurinia Pharmaceuticals Stock Is Slumping Today ↗

September 18, 2023

The biotech's premium valuation doesn't seem to be sitting well with investors.

Via The Motley Fool

Aurinia Pharmaceuticals Earnings Perspective: Return On Capital Employed ↗

May 18, 2023

Via Benzinga

Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023

November 07, 2023

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNISⓇ for Managing Lupus Nephritis

November 02, 2023

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results

November 02, 2023

From Aurinia Pharmaceuticals Inc.

Via Business Wire

This Oil Giant Is 'Not Great, Not Bad,' But Jim Cramer Says 'I'm Sticking With My Coterra' ↗

October 30, 2023

On CNBC’s "Mad Money Lightning Round," Jim Cramer said BP (NYSE: BP) is "not great, not bad." He added, "This whole group is going through a real re-evaluation.

Via Benzinga

Aurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis

October 26, 2023

From Aurinia Pharmaceuticals Inc.

Via Business Wire

CORRECTING and REPLACING Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023

October 19, 2023

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2023 and 2023 American College of Rheumatology Convergence (ACR)

October 13, 2023

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital

September 21, 2023

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic Pipelines

August 21, 2023

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results

August 03, 2023

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023

July 20, 2023

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Long Term Phase 3 Data Published in Arthritis & Rheumatology Shows LUPKYNIS® (voclosporin) Preserved Kidney Function Up to Three Years in Lupus Nephritis Patients with No New or Unexpected Adverse Events

July 19, 2023

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Why Aurinia Pharmaceuticals Stock Is Marching Higher Friday ↗

June 30, 2023

The biotech's board is exploring strategic alternatives to boost shareholder value.

Via The Motley Fool

Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

June 30, 2023

Gainers Addentax Group Corp. (NASDAQ: ATXG) shares jumped 47.3% to $9.68. Addentax Group is launching automation of artificial intelligence internet operational tools project with top...

Via Benzinga

Carnival, SMART Global, Friedman Industries And Other Big Stocks Moving Higher On Friday ↗

June 30, 2023

U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Friday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Aurinia Surges As It Explores 'Strategic Alternatives,' Including A Potential Buyout ↗

June 30, 2023

The company makes a lupus nephritis treatment that could easily bolt onto a suitor, analysts say.

Via Investor's Business Daily

Why Are Aurinia Pharmaceuticals Shares Trading Higher Today ↗

June 30, 2023

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) initiated an exploration of strategic alternatives, including a potential sale, merger, or

Via Benzinga

Why Renalytix Are Trading Higher By Over 48%; Here Are 20 Stocks Moving Premarket ↗

June 30, 2023

Gainers Renalytix Plc (NASDAQ: RNLX) shares surged 48.7% to $3.02 in pre-market trading after the company received FDA De Novo marketing authorization for its KidneyIntelX.dkd prognostic test.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

June 30, 2023

It's the final day of trading this week and we're starting off with a breakdown of the biggest pre-market stock movers worth watching today!

Via InvestorPlace

Tesla, Nike, Sigilon Therapeutics Among Top Trending Stocks Today ↗

June 29, 2023

Via Benzinga

Aurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

June 29, 2023

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy

June 20, 2023

From Aurinia Pharmaceuticals Inc.

Via Business Wire

LUPKYNIS® (voclosporin) Achieved Significantly Higher Renal Response in Lupus Nephritis Patients with High Proteinuria Compared to Patients Treated with MMF and Low Dose Steroids Alone

June 01, 2023

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees

May 26, 2023

From Aurinia Pharmaceuticals Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.